Docetaxel and cyclophosphamide as neoadjuvant chemotherapy in HER2-negative primary breast cancer.
Nakatsukasa K, Koyama H, Oouchi Y, Imanishi S, Mizuta N, Sakaguchi K, Fujita Y, Fujiwara I, Kotani T, Matsuda T, Fukuda K, Morita M, Kawakami S, Kadotani Y, Konishi E, Yanagisawa A, Taguchi T.
Nakatsukasa K, et al. Among authors: kawakami s.
Breast Cancer. 2017 Jan;24(1):63-68. doi: 10.1007/s12282-016-0666-7. Epub 2016 Jan 11.
Breast Cancer. 2017.
PMID: 26754092
Clinical Trial.